全文获取类型
收费全文 | 95599篇 |
免费 | 7188篇 |
国内免费 | 2557篇 |
专业分类
耳鼻咽喉 | 431篇 |
儿科学 | 2426篇 |
妇产科学 | 1026篇 |
基础医学 | 8015篇 |
口腔科学 | 580篇 |
临床医学 | 12023篇 |
内科学 | 19016篇 |
皮肤病学 | 352篇 |
神经病学 | 4502篇 |
特种医学 | 6764篇 |
外国民族医学 | 12篇 |
外科学 | 19359篇 |
综合类 | 14699篇 |
现状与发展 | 9篇 |
预防医学 | 2907篇 |
眼科学 | 641篇 |
药学 | 6774篇 |
47篇 | |
中国医学 | 2679篇 |
肿瘤学 | 3082篇 |
出版年
2024年 | 230篇 |
2023年 | 1425篇 |
2022年 | 2517篇 |
2021年 | 3505篇 |
2020年 | 3191篇 |
2019年 | 3334篇 |
2018年 | 3773篇 |
2017年 | 2663篇 |
2016年 | 2947篇 |
2015年 | 3189篇 |
2014年 | 6122篇 |
2013年 | 6649篇 |
2012年 | 4900篇 |
2011年 | 5427篇 |
2010年 | 4614篇 |
2009年 | 4668篇 |
2008年 | 4740篇 |
2007年 | 4861篇 |
2006年 | 4483篇 |
2005年 | 4099篇 |
2004年 | 3325篇 |
2003年 | 2793篇 |
2002年 | 2413篇 |
2001年 | 2203篇 |
2000年 | 1901篇 |
1999年 | 1690篇 |
1998年 | 1631篇 |
1997年 | 1442篇 |
1996年 | 1202篇 |
1995年 | 1134篇 |
1994年 | 1055篇 |
1993年 | 955篇 |
1992年 | 949篇 |
1991年 | 655篇 |
1990年 | 651篇 |
1989年 | 495篇 |
1988年 | 521篇 |
1987年 | 445篇 |
1986年 | 336篇 |
1985年 | 417篇 |
1984年 | 356篇 |
1983年 | 196篇 |
1982年 | 262篇 |
1981年 | 195篇 |
1980年 | 154篇 |
1979年 | 134篇 |
1978年 | 133篇 |
1977年 | 87篇 |
1976年 | 94篇 |
1975年 | 54篇 |
排序方式: 共有10000条查询结果,搜索用时 24 毫秒
101.
重组人红细胞生成素治疗肾性贫血的临床分析 总被引:1,自引:0,他引:1
目的 观察重组人红细胞生成素 (RhEPO)对肾性贫血的治疗作用。方法 根据使用EPO剂量的不同将 39例慢性肾衰竭并血液透析病人分成 4组 ,观察治疗后 2、4、12个月时与治疗前 (0月 )相比红细胞数 (RBC)、红细胞比积 (Hct)及血红蛋白含量 (Hb)的变化。结果 2 4例使用EPO10 0 - 15 0IU/ (kg·w) (6 0 0 0IU/w - 90 0 0IU/w) ,治疗后RBC、Hct、Hb较治疗前有显著升高 (P≤ 0 .0 0 1) ;5例使用EPO5 0IU/ (kg·w) (30 0 0IU/w) +间断输血患者 ,其RBC、Hct、Hb升高不显著 ;10例不用EPO而单纯输血患者 ,其RBC、Hct、Hb无明显变化 (P >0 .0 5 )。结论 EPO能较好地纠正肾性贫血 ;单纯输血不能治疗肾性贫血 相似文献
102.
Y Namba T Moriyama M Kyo K Oka Y Kokado Y Shi R Imamura N Ichimaru A Okuyama S Takahara 《Clinical transplantation》2004,18(S11):29-33
Abstract: Angiotensin-converting enzyme inhibitor (ACEI) has become recognized as agents that have renoprotective effects in the treatment of progressive renal diseases including post-transplant kidneys. Previously we demonstrated the safety and effectiveness of ACEI treatment on the hypertensive proteinuric post-transplant patients ( N = 10) who had been followed up for 12 months. However, not all patients show good response in urinary protein reduction. We aimed to analyse the histopathological factor(s) affecting the responsiveness of proteinuria to ACEI treatment. Fourteen post-transplant patients with proteinuria who were treated with ACEI and underwent allograft biopsy were analysed. Eight patients showed 50% or more reduction in proteinuria (responder). The other 6 patients showed less (< 50%) reduction in proteinuria (non-responder). There was no difference in clinical characteristics (BP, renal function, donor age, recipient body mass index), dietary sodium or protein intake, and diuretic use between the two groups. As a histopathological characteristic, glomerular size in responder group was significantly larger than that in non-responder group. This suggests that the large glomerular size at least partly contributes to the responsiveness in urinary protein reduction to ACEI treatment in kidney allograft recipients with proteinuria. 相似文献
103.
Gabriel Mircescu Dimitrie Capsa Maria Covic Mirela Gherman Caprioara Gheorghe Gluhovschi Ovidiu Golea Nicolae Ursea Liliana Garneata Vasile Cepoi Nicolae Constantinovici Adrian Covic 《Nephrology, dialysis, transplantation》2004,19(12):2971-2980
INTRODUCTION. This report describes the current status of nephrology and renal replacement therapy (RRT) in Romania, a country with previously limited facilities, highlighting national changes in the European context. METHODS: Trends in RRT development were analysed in 2003, on a national basis, using the same questionnaires as in previous surveys (1991, 1995). Survival data and prognostic risk factors were calculated retrospectively from a large representative sample of 2284 patients starting RRT between January 1, 1995 and December 31, 2001 (44% of the total RRT population investigated). RESULTS: In 2003, RRT incidence [128 per million population (p.m.p.)] and prevalence (250 p.m.p.) were six and five times higher, respectively, than in 1995. The annual rate of increase in the stock of RRT patients (11%) was supported mainly by an exponential development of the continuous ambulatory peritoneal dialysis (CAPD) population (+600%), while the haemodialysis (HD) growth rate was stable (+33%) and renal transplantation made a marginal contribution. Renal care infrastructure followed the same trend: nephrology departments (+100%) and nephrologists (+205%). The characteristics of RRT incident patients changed accordingly to current European epidemiology (increasing age and prevalence of diabetes and nephroangiosclerosis). The estimated overall survival of RRT patients in Romania was 90.6% at 1 year [confidence interval (CI) 89.4-91.8] and 62.2% at 5 years (CI 59.4-65.0). Patients' survival was negatively influenced (Cox regression analysis) by age >65 years (P < 0.001), lack of pre-dialysis monitoring by a nephrologist [P = 0.01, hazards ratio (HR) = 0.8], severe anaemia, lack of erythropoetin treatment (P < 0.001, HR = 0.6), and co-morbidity, e.g. cardiovascular diseases (P < 0.001, HR = 1.8) and diabetes mellitus (P < 0.001, HR = 2.2). CONCLUSIONS: Although the rate of increase in RRT patient stock in 1996-2003 in Romania was the highest in Europe, the prevalence remained below the European mean. As CAPD had the greatest expansion, followed by HD, an effective transplantation programme must be set up to overcome the imbalance. The quality of RRT appears to be good and survival was similar to that in other registries. Further evolution implies strategies of prevention, based on national surveys, supported by the Romanian Renal Registry. 相似文献
104.
Clinicopathological study of vesicoureteral reflux (VUR)-associated pyelonephritis in renal transplantation 总被引:1,自引:0,他引:1
K Ohba M Matsuo M Noguchi M Nishikido S Koga H Kanetake A Nazneen D Liu M S Razzaque T Taguchi 《Clinical transplantation》2004,18(S11):34-38
Abstract: We retrospectively studied the occurrence of vesicoureteral reflux (VUR)-associated pyelonephritis using renal biopsies obtained from the transplanted kidneys, and correlated the histological changes with clinical parameters. Out of a total of 131 renal biopsies performed between 1990 and 2001 on renal transplant patients at the department of Urology of Nagasaki University Graduate School of Biomedical Sciences, 12 patients showed pyuria more than twice in a single year. Seven of these 12 patients were available for determining VUR by voiding cystourethrography (VCUG). Cystoureterography demonstrated VUR in three of seven studied patients with pyuria. A histopathological examination revealed dilatation of both proximal and distal tubules in renal biopsies of transplant patients with VUR, compared to renal biopsies of transplant patients without VUR, or non-transplanted patients with thin membrane disease. One of the patients with VUR showed advanced features of chronic pyelonephritis in four consecutive biopsies at different time points, suggesting a late stage of reflux nephropathy in the transplanted kidney. We conclude from our study that the occurrence of VUR-related pyelonephritis may be one of the important long-term complications in the survival of renal allografts. 相似文献
105.
106.
107.
Darren S Parsons David A Reaveley Darrell V Pavitt Madhukar Misra Edwina A Brown 《Nephrology, dialysis, transplantation》2003,18(9):1848-1853
BACKGROUND: Studies have reported an increase in median Lipoprotein (Lp) (a) in patients with high molecular weight (HMW) apolipoprotein (apo) (a) isoforms and renal impairment. Some studies identify Lp (a) levels as a risk factor for vascular disease in renal failure whilst others have demonstrated an association with apo (a) isoform type and vascular disease. METHODS: A total of 239 patients at end-stage renal failure (ESRF) were studied prior to the initiation of dialysis. Blood was taken for Lp (a) levels and apo (a) isoforms. Clinical vascular disease (CVD) was assessed on the basis of clinical history and Rose questionnaire. The control group for Lp (a) levels consisted of 228 healthy volunteers. RESULTS: Despite a higher median Lp (a) level in those with HMW isoforms, 30% of patients had Lp (a) levels <10 mg/dl. Overall, 49% patients were identified as having CVD. Diabetes, smoking history and Lp (a) levels were significantly associated with CVD in logistic regression analysis, although when patients with low molecular weight (LMW) and HMW isoforms were analysed separately, Lp (a) levels were not significantly associated with CVD in those with LMW isoforms. The rates of CVD in those with HMW isoform and low Lp (a) levels were significantly lower than those with HMW isoforms and elevated Lp (a) levels, 34 vs 57% (P < 0.01). CONCLUSIONS: Although median Lp (a) levels in those patients at ESRF with HMW isoforms are higher than controls, in a third of such patients Lp (a) levels remain relatively low. These patients have lower rates of CVD than those with high levels of Lp (a). 相似文献
108.
蜂毒素微球经动脉介入治疗大鼠肝癌的实验研究 总被引:9,自引:0,他引:9
目的:观察蜂毒素微球(M-MS)经动脉介入对大鼠肝癌的治疗作用.方法:采用改良的复乳-液中干燥法制备蜂毒素-聚乳酸/羟乙酸微球,建立大鼠移植性肝癌模型并随机分为四组,分别经肝动脉灌注生理盐水(NS,1.5ml/kg)、蜂毒素(Melittin,0.35mg/kg)、空白微球(B-MS,10mg/kg)和蜂毒素-聚乳酸/羟乙酸微球(10mg/kg).比较治疗后各组大鼠的肿瘤生长情况、肿瘤坏死程度和生存时间.结果:与生理盐水组比较,Melittin组、B-MS组肿瘤生长受到明显抑制(P<0.01),肿瘤坏死程度以轻中度为主,但两组动物生存时间均未能明显延长(P>0.05).M-MS组与NS组、Melittin组及B-MS组相比,肿瘤生长抑制显著(P<0.01),肿瘤坏死更广泛、更彻底,且经蜂毒素微球治疗的大鼠生存期显著延长(P<0.01).结论:蜂毒素以药物微球的剂型经肝动脉给药,抗肿瘤效果明显优于单纯的蜂毒素和空白微球. 相似文献
109.
目的 探讨冠状动脉瘘的影像特征、鉴别诊断及彩色多普勒超声在飞行员改装体检中的医学鉴定价值.方法 分析1例飞行员左冠状动脉-肺动脉瘘超声图像特征并复习相关文献.探讨应用彩色多普勒超声检查在飞行员改装体检中的必要性.结果 彩色多普勒超声显示心底部心肌间走行迂曲的异常血流束,经主肺动脉外侧壁注入肺动脉内.超声诊断:左冠状动脉-肺动脉瘘.飞行结论:改装并原机种飞行不合格结论彩色多普勒超声检查能清晰显示冠状动脉瘘,并能追踪观察其走行、部位、内径和大小,超声诊断与冠状动脉造影结果相符.冠状动脉瘘早期无特异性临床表现,彩色多普勒超声心动图诊断冠状动脉瘘直接、安全、快捷,具有重要的临床价值,是明确诊断的首选方法. 相似文献
110.
Prevalence of silent myocardial ischemia in asymptomatic individuals with subclinical atherosclerosis detected by electron beam tomography 总被引:3,自引:0,他引:3
Anand D. Vijay Lim Eric Raval Usha Lipkin David Lahiri Avijit 《Journal of nuclear cardiology》2004,11(4):450-457
BACKGROUND: Electron beam tomography coronary calcium imaging is an evolving technique for the early detection of coronary atherosclerosis, and recent studies have established its prognostic value in asymptomatic individuals. The relationship of coronary artery calcium scores (CAC) to obstructive coronary artery disease (CAD) has been poorly studied but is clinically relevant because it determines which individuals are likely to benefit from revascularization procedures. Hence, we prospectively evaluated the prevalence of myocardial ischemia in asymptomatic patients with cardiovascular risk factors and subclinical atherosclerosis. METHODS AND RESULTS: We studied 864 asymptomatic patients with no previous CAD but with cardiovascular risk factors, referred for electron beam tomography coronary calcium imaging to our institution over an 18-month period. From this group, 220 consecutive patients (85% men; mean age, 61 +/- 9 years; age range, 31-84 years) with moderate to severe atherosclerotic disease (coronary calcium score > or =100 Agatston units) were prospectively evaluated by technetium 99m sestamibi single photon emission computed tomography (SPECT). Patients were followed up (mean follow-up, 14 months) and data regarding their subsequent clinical management recorded. Of the 220 patients, 119 had moderate atherosclerosis (CAC score of 100-400 Agatston units) and 101 had severe atherosclerosis (CAC score > or =400 Agatston units). Abnormal SPECT findings were seen in 18% of patients with moderate atherosclerosis (n = 21) and 45% of patients with severe atherosclerosis (n = 45). Increasing severity of atherosclerosis was related to increasing ischemic burden (summed difference score = 1 +/- 0.2 for CAC score of 100-400 Agatston units and 3.2 +/- 0.5 for CAC score > or =400 Agatston units). In a multivariate linear regression model incorporating risk factors, CAC was the only predictor of silent ischemia. CONCLUSION: In comparison to previously published data, we detected a higher prevalence of silent ischemia even in patients with moderate coronary atherosclerosis (18%). This may reflect the differing risk factor profile of our patient population. When coronary calcium screening is used to preselect asymptomatic patients with cardiovascular risk factors for myocardial perfusion imaging, the optimum coronary calcium score threshold will depend on the population prevalence of risk factors and asymptomatic obstructive CAD. 相似文献